Neutrophil-lymphocyte ratio quantitates immune system status predicting treatment response and prognosis. Elevated ratios indicate neutrophilic dominance reflecting acute inflammation. Reduced ratios suggest lymphocytic predominance. Ratio changes during treatment track immune modulation. Prognostic utility varies by disease context.
Biomarker assessment informs treatment selection. Regulatory submissions incorporate biomarker validation. Clinical outcomes correlate with ratio changes. Post-approval monitoring employs longitudinal assessment. Emerging immunological markers improve predictive value.
General Biopharmaceutical Concepts
Neutrophil-Lymphocyte Ratio
The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory biomarker calculated from blood cell counts to assess disease severity, prognosis or treatment response.
Continue Exploring
Browse over 900 biopharmaceutical terms across biologics, ADCs, cell & gene therapy, CMC, clinical development and manufacturing.
Browse Glossary →